BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17517052)

  • 1. Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients.
    Ishikawa E; Tsuboi K; Yamamoto T; Muroi A; Takano S; Enomoto T; Matsumura A; Ohno T
    Cancer Sci; 2007 Aug; 98(8):1226-33. PubMed ID: 17517052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article.
    Muragaki Y; Maruyama T; Iseki H; Tanaka M; Shinohara C; Takakura K; Tsuboi K; Yamamoto T; Matsumura A; Matsutani M; Karasawa K; Shimada K; Yamaguchi N; Nakazato Y; Sato K; Uemae Y; Ohno T; Okada Y; Hori T
    J Neurosurg; 2011 Aug; 115(2):248-55. PubMed ID: 21568657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, placebo-controlled phase IIb trial of an autologous formalin-fixed tumor vaccine for newly diagnosed glioblastomas.
    Muragaki Y; Ishikawa E; Maruyama T; Nitta M; Saito T; Ikuta S; Komori T; Kawamata T; Yamamoto T; Tsuboi K; Matsumura A; Nakamura H; Kuroda J; Abe T; Momii Y; Saito R; Tominaga T; Tabei Y; Suzuki I; Arakawa Y; Miyamoto S; Matsutani M; Karasawa K; Nakazato Y; Maebayashi K; Hashimoto K; Ohno T
    J Neurosurg; 2023 Aug; 139(2):344-354. PubMed ID: 36670529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma - three case reports - .
    Sakamoto N; Ishikawa E; Yamamoto T; Satomi K; Nakai K; Sato M; Enomoto T; Morishita Y; Takano S; Ohno T; Tsuboi K; Matsumura A
    Neurol Med Chir (Tokyo); 2011; 51(4):319-25. PubMed ID: 21515959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.
    Ardon H; Van Gool S; Lopes IS; Maes W; Sciot R; Wilms G; Demaerel P; Bijttebier P; Claes L; Goffin J; Van Calenbergh F; De Vleeschouwer S
    J Neurooncol; 2010 Sep; 99(2):261-72. PubMed ID: 20146084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.
    Izumoto S; Tsuboi A; Oka Y; Suzuki T; Hashiba T; Kagawa N; Hashimoto N; Maruno M; Elisseeva OA; Shirakata T; Kawakami M; Oji Y; Nishida S; Ohno S; Kawase I; Hatazawa J; Nakatsuka S; Aozasa K; Morita S; Sakamoto J; Sugiyama H; Yoshimine T
    J Neurosurg; 2008 May; 108(5):963-71. PubMed ID: 18447714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report.
    Liau LM; Black KL; Martin NA; Sykes SN; Bronstein JM; Jouben-Steele L; Mischel PS; Belldegrun A; Cloughesy TF
    Neurosurg Focus; 2000 Dec; 9(6):e8. PubMed ID: 16817691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.
    Steiner HH; Bonsanto MM; Beckhove P; Brysch M; Geletneky K; Ahmadi R; Schuele-Freyer R; Kremer P; Ranaie G; Matejic D; Bauer H; Kiessling M; Kunze S; Schirrmacher V; Herold-Mende C
    J Clin Oncol; 2004 Nov; 22(21):4272-81. PubMed ID: 15452186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
    Hunn MK; Bauer E; Wood CE; Gasser O; Dzhelali M; Ancelet LR; Mester B; Sharples KJ; Findlay MP; Hamilton DA; Hermans IF
    J Neurooncol; 2015 Jan; 121(2):319-29. PubMed ID: 25366363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
    Vymazal J; Wong ET
    Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
    Inogés S; Tejada S; de Cerio AL; Gállego Pérez-Larraya J; Espinós J; Idoate MA; Domínguez PD; de Eulate RG; Aristu J; Bendandi M; Pastor F; Alonso M; Andreu E; Cardoso FP; Valle RD
    J Transl Med; 2017 May; 15(1):104. PubMed ID: 28499389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma.
    Kuang M; Peng BG; Lu MD; Liang LJ; Huang JF; He Q; Hua YP; Totsuka S; Liu SQ; Leong KW; Ohno T
    Clin Cancer Res; 2004 Mar; 10(5):1574-9. PubMed ID: 15014006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial.
    Cho DY; Yang WK; Lee HC; Hsu DM; Lin HL; Lin SZ; Chen CC; Harn HJ; Liu CL; Lee WY; Ho LH
    World Neurosurg; 2012; 77(5-6):736-44. PubMed ID: 22120301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
    Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
    Front Immunol; 2018; 9():727. PubMed ID: 29910795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human umbilical vein endothelial cell vaccine therapy in patients with recurrent glioblastoma.
    Tanaka M; Tsuno NH; Fujii T; Todo T; Saito N; Takahashi K
    Cancer Sci; 2013 Feb; 104(2):200-5. PubMed ID: 23106822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas.
    Okada H; Lieberman FS; Walter KA; Lunsford LD; Kondziolka DS; Bejjani GK; Hamilton RL; Torres-Trejo A; Kalinski P; Cai Q; Mabold JL; Edington HD; Butterfield LH; Whiteside TL; Potter DM; Schold SC; Pollack IF
    J Transl Med; 2007 Dec; 5():67. PubMed ID: 18093335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
    Kuranishi F; Ohno T
    World J Surg Oncol; 2013 Jun; 11():127. PubMed ID: 23734861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial.
    Ji N; Zhang Y; Liu Y; Xie J; Wang Y; Hao S; Gao Z
    JCI Insight; 2018 May; 3(10):. PubMed ID: 29769450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients.
    Wheeler CJ; Black KL; Liu G; Mazer M; Zhang XX; Pepkowitz S; Goldfinger D; Ng H; Irvin D; Yu JS
    Cancer Res; 2008 Jul; 68(14):5955-64. PubMed ID: 18632651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.